Currently, inhibitors of ANGPTL3 have been extensively studied in cardiovascular disease, and suppression of ANGPTL3 is protective in nephrotic syndrome [16, 17]; in the future, this inhibitor would be a candidate for hyperlipidemia-related kidney injury. Here, ANGPTL3 is linked to cardiovascular disorder.